WhatsApp Skip to main content

Dr. Harsh J Shah

Which GIST Studies Changed Treatment, and What Is New?

Last updated: 17-Nov-2026

Tapping Book on WhatsApp will likely open the WhatsApp app on your phone.

Dr Harsh Shah, stomach cancer surgeon, Ahmedabad

Dr Harsh Shah
MS, MCh (Surgical Gastroenterology), DrNB (Surgical Gastroenterology)
Registered with Gujarat Medical Council, Reg. No. G-38738
Stomach Cancer Surgeon
Dr. Jivraj Mehta Hospital, Vasna, Ahmedabad · 18 years of experience

In short

A small set of large studies built today’s GIST care. They tell us who needs tablets after surgery, for how long, and which medicine comes next.

Imatinib after surgery lowers the chance that a high-risk GIST returns, and three years works better than one. A few very high-risk patients may gain from longer.

New work looks at tumour DNA in the blood, better later medicines and rare gene types. None of it has replaced the usual plan yet.

For the whole story of GIST, from the first test to imatinib and surgery, read our GIST treatment in Ahmedabad page. This post explains the key studies behind that care and what is new.

How should you read a GIST study?

Check the gene type of the patients first. A result in one gene type may not hold for another, so a headline can mislead.

  • Most patients in the big studies had a change in KIT exon 11. A result seen in them may not carry over to KIT exon 9, PDGFRA or SDH-deficient tumours.
  • Most studies after surgery compare how long to take imatinib. They do not ask whether to treat at all, which one early study settled.
  • Studies of later medicines test one step at a time. The order we use is built from many separate studies, not from one study of the whole order.

Few Indian patients joined these studies. So we also look at hospital series from India, which are covered below.

Which studies cover tablets after surgery?

Five studies shape the plan after surgery. Together they show that imatinib lowers the chance of a return, and that three years beats one year for high-risk tumours.

Studies of imatinib after surgery and what each one taught
StudyWhat it askedWhat it showed
ACOSOG Z9001 (2009)One year of imatinib against dummy tablets, after surgery for a GIST of 3 cm or moreFewer tumours came back with imatinib, so the medicine works after surgery
SSGXVIII (2012, long follow-up 2020)Three years against one year, in high-risk tumoursThree years kept more people free of a return and helped them live longer; it became the usual plan
EORTC 62024 (2015, 2021)Two years against no tabletsNo clear gain, so two years looks too short
PERSIST-5 (2018)Five years, in one group with no comparisonMost returns came after patients stopped, so the shield lasts only while the tablet is taken
IMADGIST (2024)Three more years, for those who stayed clear after three yearsFewer returns with longer use in a very high-risk group; overall survival did not differ at the time of report

What does this mean for a patient? A high-risk tumour that responds to imatinib is usually treated for three years. A lower-risk tumour may need less, or none, and your risk group decides.

The extra three years are not for everyone. They suit only the very highest risk, and the choice is made with the whole team.

One more lesson matters. The weeks and months after the last tablet are when a return is most likely. Scans are therefore kept close in that period.

What do studies say about tablets before surgery?

Imatinib before surgery can shrink a large or awkward tumour so that it can be removed safely. This rests on smaller studies, not on trials against surgery alone.

  • RTOG 0132 gave imatinib for a short period before surgery. It showed that this is safe and does not raise the risk of the operation.
  • APOLLON followed patients with a large tumour who had imatinib until the tumour shrank most. Most could then be operated on without leaving tumour behind.
  • Today, tablets are continued for months with repeat scans until the shrinkage stops, not for a fixed short period.

It is a way to make surgery safer, not a proven way to live longer. We choose it when an upfront operation would be risky or incomplete, for example in a low rectal tumour.

What did the early studies show for spread disease?

Imatinib gave lasting control in many people whose GIST had spread. The usual starting dose is 400 mg a day, and a higher dose suits one gene type.

Imatinib studies in GIST that cannot be removed or has spread
StudyWhat it askedWhat it showed
B2222 (2002)Does imatinib work in advanced GIST?Yes. Many tumours shrank or stopped growing, and GIST became a model for targeted medicine
EORTC 62005 and S0033 (2004, 2008)400 mg against 800 mg a dayNo overall difference in survival, and the higher dose caused more side effects
MetaGIST (2010)The same question, with both studies pooledPatients with a KIT exon 9 change did better on 800 mg; others did not

So 800 mg is not a stronger plan for everyone. It is a specific choice for exon 9. It also suits a patient who takes the tablets properly and still shows growth on 400 mg.

Skipped tablets and a low blood level can look like drug failure. Both are checked before a patient is told that imatinib has stopped working.

What if imatinib stops working?

Three medicines follow in turn: sunitinib, regorafenib and ripretinib. Each was shown to hold the tumour longer than dummy tablets in a patient who had run out of options.

Medicines after imatinib and the study behind each
MedicineStudyWhat it showedUsual place
SunitinibPhase 3 against dummy tablets (2006)Much longer time before the tumour grew againSecond medicine
RegorafenibGRID (2013)Longer control than dummy tablets; hand and foot skin trouble is commonThird medicine
RipretinibINVICTUS (2020)Longer control than dummy tablets, with milder side effectsFourth medicine

A later study, INTRIGUE, tested ripretinib against sunitinib as the second medicine. Ripretinib was not better overall, so sunitinib stays in second place.

A blood-DNA sub-study did hint that ripretinib suits certain resistance changes. This is a research signal, not yet a standard.

Which gene change needs a different medicine?

A PDGFRA D842V change does not respond to imatinib. For it, a medicine called avapritinib produced a high response rate in the NAVIGATOR study.

  • NAVIGATOR was a smaller early study. The response in the D842V group was strong, and it is now the usual choice for that change.
  • VOYAGER compared avapritinib with regorafenib in patients who did not have a selected gene change. Avapritinib was not better.
  • Avapritinib can cause memory and focus problems in some patients, so it is kept for those who gain the most.

The lesson is simple. A medicine that works well for one gene change may do no better than the old one in everyone else.

What does this mean for patients in India?

The landmark studies had few Indian patients, but Indian hospital series point the same way. What decides the outcome here is mostly taking the tablets without a break.

  • Generic imatinib has been sold in India since 2008. It is bioequivalent, and it made a three-year course possible for many families.
  • Gene testing is still not done everywhere, and SDH-deficient and NF1-linked tumours are often missed.
  • Later medicines such as regorafenib, ripretinib and avapritinib cost far more, so access is the real limit at that stage.

Ask for a gene report before any tablet is started. Our post on how a GIST is confirmed with CT, scope and biopsy explains when it is sent. To see how the type and risk group are worked out, read how common GIST is and what types exist.

What is new in GIST care?

New work is aimed at second-line medicine, blood tests for tumour DNA and rare gene types. Most of it is still in trials and is not yet routine.

  • Bezuclastinib is being tested with sunitinib against sunitinib alone as a second medicine. Results are awaited.
  • Blood tests for tumour DNA may help choose a second medicine and spot a return early. They are not yet a standard.
  • For intermediate-risk tumours, researchers are testing shorter courses and gene-guided length of treatment.
  • Immunotherapy alone has been disappointing in GIST, and combinations are still early.
  • NF1-linked and SDH-deficient tumours respond poorly to imatinib. Patients with these should be seen at a reference centre that runs trials.

Treat a news headline with care. A result becomes a plan only after a larger study confirms it. It must also fit your gene type, your risk group and your scans.

Frequently asked questions

Why do only a few studies guide GIST care?

GIST is rare, so large trials are hard to run. A small set of well-built studies carries most of the weight, and each answers one clear question.

How long should imatinib be taken after surgery?

For a high-risk tumour that responds to imatinib, three years is the usual plan. A few very high-risk patients may be offered longer. Lower-risk tumours may need less, or none.

Can I stop imatinib if my scan is clear?

Not on your own. Studies show that most returns happen after the tablets are stopped. The length of treatment is set with your doctor, based on your risk group.

Is generic imatinib as good as the brand?

Yes. Indian generic imatinib is bioequivalent to the original. Differences in outcome come from missed doses and delays, not from the quality of the tablet.

Does 800 mg mean a stronger treatment?

Not for everyone. A higher dose helps patients with a KIT exon 9 change. It also helps those who still show growth on 400 mg despite proper use. For others it adds side effects.

Is a blood test for tumour DNA ready for routine use?

Not yet. It shows promise for choosing a second medicine and spotting a return early. At present it is used mostly in research and at reference centres.

Should I join a clinical trial?

Ask about it if you have a rare gene type, or if the usual medicines have stopped working. Trials are run at reference centres, and your doctor can help you find one.

Related pages

For the full picture of GIST and its treatment, start at the GIST treatment in Ahmedabad page. For questions before you travel, call +91-63555-64601.

Where Dr Harsh Shah sees patients and operates

Dr Harsh Shah — Dr. Jivraj Mehta Hospital, Vasna, Ahmedabad
Dr. Jivraj Mehta Hospital, Dr Jivraj Mehta Marg, Vasna, Ahmedabad 380007.
Consultations, review of reports and scans, operations and follow-up. OPD Monday to Saturday, 9 am to 5 pm.
Appointments: +91-63555-64601 · +91-63590-11009 · Hospital 079-2663 6363
Directions to the hospital · WhatsApp +91-63555-64601

Read about imatinib or a new GIST medicine and wonder if it applies to you? A study result helps only when it fits your gene type and your risk group. Dr Harsh Shah, a stomach cancer surgeon in Ahmedabad, will match the studies to your own reports. Bring your scans, biopsy report and gene report. You can call us or book by message. Call For Appointment Book on WhatsApp Tapping Book on WhatsApp will likely open the WhatsApp app on your phone.

Tapping Book on WhatsApp will likely open the WhatsApp app on your phone.

Get health updates from Dr Harsh Shah on WhatsApp

Swasth Parivar: every week, practical advice on recovery, diet and warning signs. No advertising. Stop any time.

Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.

Dr. Harsh J Shah
Dr Harsh Shah, Gastro, Cancer & Laparoscopic Surgeon, Ahmedabad
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.